Neonatal alloimmune neutropenia is due to maternal production of antibodies directed against neutrophil specific antigens (NA1, NA2, NB1, NC1) reacting with fetal-neonatal and paternal neutrophils.

X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...

Close monitoring via weekly complete blood counts (CBCs) for the first 2 months is essential to mitigate risks, according to Zeidan. Supportive care such as platelet transfusions or growth factors may ...

The European Medicines Agency (EMA) has approved Ryzneuta (efbemalenograstim alfa) as a treatment to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults treated with ...

Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors PURPOSE: To compare meropenem, a carbapenem antibiotic, with ...

BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food ...

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new ...

AbbVie (ABBV) announced it will unveil new data from its robust antibody-drug conjugate platform at the 2025 European Society ...